Skip to main content
Premium Trial:

Request an Annual Quote

Two Drugs, One Possible Issue

Premium

The US Food and Drug Administration rejected Medtronic's bone-growth product Amplify back in March, due to cancer risk concerns. Amplify is a higher-dose version of the company's Infuse product. At a conference this week, Stanford University's Eugene Carragee said that not all of Medtronic's clinical trial data had been made public before, and that data "showed a significantly higher number of cancers in the study group that received Amplify when compared to a control group that received a bone graft as part of a spinal fusion," The New York Times reports. Carragee added that the Amplify results may also be of importance for Infuse, as the products have the same active ingredient and as some doctors prescribe Infuse at high doses, closer to those seen in Amplify.

In August, Medtronic awarded Yale University $2.5 million to review Infuse study data. That review is expected to be finished next year, and a spokesperson tells the Times that that review "will address the safety and effectiveness" of Infuse.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.